title: Increasing costs of imaging and treatment of subfoveal choroidal neovascularization in the anti-vascular endothelial growth factor era.
authors.forename: John T
authors.initials: JT
authors.lastname: Thompson
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000191:economics*; D003941:Diagnostic Techniques, Ophthalmological / Q000191:economics*; D016527:Drug Costs; D005451:Fluorescein Angiography / Q000191:economics; D005584:Fovea Centralis; D017048:Health Care Costs / Q000639:trends*; D006801:Humans; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence / Q000191:economics*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab